Zandl-Lang M, Zullig T, Holzer M, Eichmann T, Darnhofer B, Schwerin-Nagel A
J Neurol. 2025; 272(3):183.
PMID: 39904776
PMC: 11794407.
DOI: 10.1007/s00415-025-12909-4.
Senol H, Yildiz G, Polat A, Aydin A, Hiz A, Soylu A
Brain Behav. 2025; 15(1):e70221.
PMID: 39829133
PMC: 11743982.
DOI: 10.1002/brb3.70221.
Bekircan-Kurt C, Subramanian S, Chagat S, MacKenzie S, Iammarino M, Reash N
Muscle Nerve. 2025; 71(3):414-421.
PMID: 39744899
PMC: 11799403.
DOI: 10.1002/mus.28329.
Gajewska E, Flicinski J, Sobieska M, Michalska J, Zarowski M, Steinborn B
Front Genet. 2024; 15:1483903.
PMID: 39649095
PMC: 11621056.
DOI: 10.3389/fgene.2024.1483903.
Guerra M, Marini A, Pagliarini V, Pitolli C, Coratti G, Bonvissuto D
Mol Neurobiol. 2024; .
PMID: 39592557
DOI: 10.1007/s12035-024-04605-7.
Efficacy of Nusinersen Treatment in Type 1, 2, and 3 Spinal Muscular Atrophy: Real-World Data from a Single-Center Study.
Lemska A, Ruminski P, Szymarek J, Studzinska S, Mazurkiewicz-Beldzinska M
Neurol Int. 2024; 16(6):1266-1278.
PMID: 39585055
PMC: 11587074.
DOI: 10.3390/neurolint16060096.
Intersession Intra-Rater and Inter-Rater Reliability of Myotonometer for Upper and Lower Extremity Muscles in Children with Spinal Muscular Atrophy.
Kutluturk Yikilmaz S, Saldiran T, Ozturk O, Oktem S
Diagnostics (Basel). 2024; 14(20).
PMID: 39451623
PMC: 11506227.
DOI: 10.3390/diagnostics14202300.
A 5-year natural history study in LAMA2-related muscular dystrophy and SELENON-related myopathy: the Extended LAST STRONG study.
de Laat E, Houwen-van Opstal S, Bouman K, van Doorn J, Cameron D, van Alfen N
BMC Neurol. 2024; 24(1):409.
PMID: 39443859
PMC: 11515704.
DOI: 10.1186/s12883-024-03852-4.
Acceptability, validity and responsiveness of inertial measurement units for assessing motor recovery after gene therapy in infants with early onset spinal muscular atrophy: a prospective cohort study.
Barrois R, Tervil B, Cacioppo M, Barnerias C, Deladriere E, Leloup-Germa V
J Neuroeng Rehabil. 2024; 21(1):183.
PMID: 39415296
PMC: 11483959.
DOI: 10.1186/s12984-024-01477-9.
Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy.
Zhang Q, Hong Y, Brusa C, Scoto M, Cornell N, Patel P
Sci Rep. 2024; 14(1):23491.
PMID: 39379509
PMC: 11461652.
DOI: 10.1038/s41598-024-74338-z.
Outcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.
Goedeker N, Rogers A, Fisher M, Arya K, Brandsema J, Farah H
Muscle Nerve. 2024; 70(6):1247-1256.
PMID: 39370660
PMC: 11560615.
DOI: 10.1002/mus.28267.
Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy.
Panicucci C, Sahin E, Bartolucci M, Casalini S, Brolatti N, Pedemonte M
Cell Mol Life Sci. 2024; 81(1):393.
PMID: 39254732
PMC: 11387582.
DOI: 10.1007/s00018-024-05426-6.
A Multicenter Cross-Sectional Study of the Swiss Cohort of LAMA2-Related Muscular Dystrophy.
Enzmann C, Steiner L, Pospieszny K, Zweier C, Plattner K, Baumann D
J Neuromuscul Dis. 2024; 11(5):1021-1033.
PMID: 39213089
PMC: 11380305.
DOI: 10.3233/JND-240023.
Rehabilitation Strategies for Patients With Spinal Muscular Atrophy in the Era of Disease-Modifying Therapy.
Shin H
Ann Rehabil Med. 2024; 48(4):229-238.
PMID: 39210748
PMC: 11372281.
DOI: 10.5535/arm.240046.
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study.
Pane M, Stanca G, Coratti G, D Amico A, Sansone V, Berti B
Eur J Pediatr. 2024; 183(11):4735-4745.
PMID: 39210071
PMC: 11473555.
DOI: 10.1007/s00431-024-05735-9.
Exploring the Influence of Concurrent Nutritional Therapy on Children with Spinal Muscular Atrophy Receiving Nusinersen Treatment.
Pinar E, Ayvaz B, Akkus E, Ulkersoy I, Dilek T, Zindar Y
Children (Basel). 2024; 11(8).
PMID: 39201821
PMC: 11352384.
DOI: 10.3390/children11080886.
Functional and Structural Changes in Patients with Spinal Muscular Atrophy Treated in Poland during 12-Month Follow-Up: A Prospective Cohort Study.
Bieniaszewska A, Sobieska M, Gajewska E
J Clin Med. 2024; 13(14).
PMID: 39064272
PMC: 11278073.
DOI: 10.3390/jcm13144232.
A Five-Year Review of Newborn Screening for Spinal Muscular Atrophy in the State of Utah: Lessons Learned.
Wong K, McIntyre M, Cook S, Hart K, Wilson A, Moldt S
Int J Neonatal Screen. 2024; 10(3).
PMID: 39051410
PMC: 11270276.
DOI: 10.3390/ijns10030054.
Identification of the most relevant aspects of spinal muscular atrophy (SMA) with impact on the quality of life of SMA patients and their caregivers: the PROfuture project, a qualitative study.
de Lemus M, Cattinari M, Pascual S, Medina J, Garcia M, Magallon A
J Patient Rep Outcomes. 2024; 8(1):78.
PMID: 39044101
PMC: 11266339.
DOI: 10.1186/s41687-024-00758-0.
[Clinical efficacy of nusinersen sodium in the treatment of children with spinal muscular atrophy].
Guo J, Wu Y, Zhang L, Ji H, Zhou N, Hu X
Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(7):743-749.
PMID: 39014952
PMC: 11562047.
DOI: 10.7499/j.issn.1008-8830.2401082.